<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1003">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739020</url>
  </required_header>
  <id_info>
    <org_study_id>20-1001</org_study_id>
    <nct_id>NCT04739020</nct_id>
  </id_info>
  <brief_title>Aerosols in PCR SARS-CoV-2 Positive and Negative Patients</brief_title>
  <official_title>Measurement of Respiratory Aerosols in PCR SARS-CoV-2 Positive and Negative Children and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Palas GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will investigate respiratory aerosols in SARS-CoV-2 (Severe Acute&#xD;
      Respiratory Syndrome Corona Virus 2) positive and negative children and adults with the&#xD;
      Resp-Aer-Meter (Palas GmbH). For this purpose, first, the measurement of respiratory aerosols&#xD;
      (particle sizes and concentration) with the Resp-Aer-Meter will be established. Thereafter, a&#xD;
      comparison between polymerase chain reaction (PCR) SARS-CoV-2 positive and negative&#xD;
      participants (children and adults) will be conducted. In addition to the measurement of&#xD;
      aerosols, the clinical symptoms, lung function (FEV1) and laboratory inflammatory markers&#xD;
      will be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corona virus disease 2019 (COVID-19) is a viral illness caused by SARS-CoV-2. Current&#xD;
      research suggests that the SARS-CoV-2 infection is primarily spread through droplets and&#xD;
      aerosols. As per current literature, the spread through asymptomatic carriers, as well as&#xD;
      highly contagious carriers ('super spreader') play an important role in the infectiousness of&#xD;
      the virus. It is currently unclear, if the contagiousness of children differs from adults.&#xD;
&#xD;
      In the proposed investigation, measurement of the particle size and concentration in&#xD;
      respiratory aerosols will be conducted via the Resp-Aer-Meter (Palas GmbH). First step will&#xD;
      be to establish the measurements with this new device. Thereafter, a comparison between PCR&#xD;
      SARS-CoV-2 positive and negative participants, as well as between children and adults, will&#xD;
      be conducted. In addition to the measurement of aerosols, the clinical symptoms suggestive of&#xD;
      COVID-19, lung function (FEV1) and laboratory inflammatory markers, if available, will be&#xD;
      analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aerosol concentration in PCR SARS-CoV-2 positive and negative participants</measure>
    <time_frame>Each patient visit will take about 1-2 hours.</time_frame>
    <description>Distinction between PCR SARS-CoV-2 positive and negative participants via aerosol measurement. Especially participants with high aerosol concentrations should be detected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in aerosol concentration over time in PCR SARS-CoV-2 positive participants</measure>
    <time_frame>7 days</time_frame>
    <description>Characterization of longitudinal change in aerosol concentration over the course of illness in PCR SARS-CoV-2 positive patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aerosol concentration in children and adults</measure>
    <time_frame>Each patient visit will take about 1-2 hours.</time_frame>
    <description>Distinction between children and adults via aerosol measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative and quantitative virus detection in respiratory secretions of patients with high aerosol concentrations.</measure>
    <time_frame>Each patient visit will take about 1-2 hours.</time_frame>
    <description>Quantitative and qualitative virus PCR measurements of respiratory secretions in participants with aerosol concentrations &gt; 5000/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cofounder Analysis</measure>
    <time_frame>Each patient visit will take about 1-2 hours.</time_frame>
    <description>Investigation of change in aerosol concentration due to confounders, such as age, sex, other viral illness, lung function, height, weight, BMI and smoking status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aerosol concentration and clinical symptoms in PCR SARS-CoV-2 positive participants</measure>
    <time_frame>Each patient visit will take about 1-2 hours.</time_frame>
    <description>Correlation between clinical symptoms and results of aerosol measurement in PCR SARS-CoV-2 positive participants. Determination if more symptoms lead to higher aerosol concentrations.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>PCR SARS-CoV-2 Negative Adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy adults with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of parents of participating children and other healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCR SARS-CoV-2 Positive Adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adults with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic parents that are in the hospital with their children and symptomatic adults that are admitted to the infectious disease ward.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCR SARS-CoV-2 Negative Children</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of children admitted to the Children's Hospital or presenting for planned diagnostic testing or follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCR SARS-CoV-2 Positive Children</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic children that are admitted to the Children's Hospital for reasons other than COVID-19 and symptomatic children.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Resp-Aer-Meter</intervention_name>
    <description>Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.</description>
    <arm_group_label>PCR SARS-CoV-2 Negative Adults</arm_group_label>
    <arm_group_label>PCR SARS-CoV-2 Negative Children</arm_group_label>
    <arm_group_label>PCR SARS-CoV-2 Positive Adults</arm_group_label>
    <arm_group_label>PCR SARS-CoV-2 Positive Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.</description>
    <arm_group_label>PCR SARS-CoV-2 Negative Adults</arm_group_label>
    <arm_group_label>PCR SARS-CoV-2 Negative Children</arm_group_label>
    <arm_group_label>PCR SARS-CoV-2 Positive Adults</arm_group_label>
    <arm_group_label>PCR SARS-CoV-2 Positive Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations</intervention_name>
    <description>Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (&gt;5000/L).</description>
    <arm_group_label>PCR SARS-CoV-2 Negative Adults</arm_group_label>
    <arm_group_label>PCR SARS-CoV-2 Negative Children</arm_group_label>
    <arm_group_label>PCR SARS-CoV-2 Positive Adults</arm_group_label>
    <arm_group_label>PCR SARS-CoV-2 Positive Children</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 years or older&#xD;
&#xD;
          -  SARS-CoV-2 PCR testing within the last 3 days&#xD;
&#xD;
          -  Ability to capture extend and consequences of the study&#xD;
&#xD;
          -  Written informed consent of patient and, if applicable, of caregiver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 6 years&#xD;
&#xD;
          -  Inability to participate in aerosol measurement&#xD;
&#xD;
          -  Inability to participate in Spirometry&#xD;
&#xD;
          -  Inability to capture extend and consequences of the study&#xD;
&#xD;
          -  Only for arm 1 (PCR SARS-CoV-2 negative adults): chronic disease with&#xD;
             immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Desiree Gutmann, MD</last_name>
    <phone>004915117190498</phone>
    <email>desiree.gutmann@kgu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Zielen, Professor</last_name>
    <phone>0049696301</phone>
    <phone_ext>83349</phone_ext>
    <email>stefan.zielen@kgu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe University Hospital</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree Gutmann, MD</last_name>
      <phone>004915117190498</phone>
      <email>desiree.gutmann@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Zielen, Professor</last_name>
      <phone>0049696301</phone>
      <phone_ext>83349</phone_ext>
      <email>stefan.zielen@kgu.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Stefan Zielen</investigator_full_name>
    <investigator_title>Professor Stefan Zielen</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Aerosol</keyword>
  <keyword>SARS-CoV-2</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized data will be provided of the investigated cohort</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After end of study, anticipated between June and December 2021</ipd_time_frame>
    <ipd_access_criteria>The data will be available after the end of study and successful publication of the results (anticipated June 2022) for 10 years</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

